The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Open accessAbstract
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Self-citationEl-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Self-citationCabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Self-citationGlobal Burden of Disease Liver Cancer Collaboration, Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3055 · Cited by 1,987
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Ryerson, A. B., Eheman, C. R., Altekruse, S. F., Ward, J. W., Jemal, A., Sherman, R. L., Henley, S. J., Holtzman, D., Lake, A., Noone, A., et al. (2016) · Cancer · doi:10.1002/cncr.29936 · Cited by 945
Zhu, A. X., Park, J. O., Ryoo, B.-Y., Yen, C.-J., Poon, R., Pastorelli, D., Blanc, J.-F., Chung, H. C., Baron, A. D., Pfiffer, T. E. F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 846
Self-citationBruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Siegel, A. B., Cohen, E. I., Ocean, A., Lehrer, D., Goldenberg, A., Knox, J. J., Chen, H., Clark-Garvey, S., Weinberg, A., Mandeli, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9947 · Cited by 506
Qin, S., Bai, Y., Lim, H. Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.-S., Bhudhisawasdi, V., Kang, W. K., Zhou, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5643 · Cited by 500
Zhu, A. X., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Muzikansky, A., Horgan, K., Sheehan, S., Hale, K. E., Enzinger, P. C., Bhargava, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9130 · Cited by 388
Thomas, M. B., Morris, J. S., Chadha, R., Iwasaki, M., Kaur, H., Lin, E., Kaseb, A., Glover, K., Davila, M., & Abbruzzese, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3301 · Cited by 334
Population attributable fractions of risk factors for hepatocellular carcinoma in the United States
Makarova‐Rusher, O. V., Altekruse, S. F., McNeel, T. S., Ulahannan, S., Duffy, A. G., Graubard, B. I., Greten, T. F., & McGlynn, K. A. (2016) · Cancer · doi:10.1002/cncr.29971 · Cited by 332
Cheng, A.-L., Guan, Z., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Yang, T.-S., Tak, W. Y., Pan, H., Yu, S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.006 · Cited by 259
Miller, A. A., Murry, D. J., Owzar, K., Hollis, D. R., Kennedy, E. B., Abou-Alfa, G., Desai, A., Hwang, J., Villalona-Calero, M. A., Dees, E. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0931 · Cited by 206
Non-viral causes of hepatocellular carcinoma
Blonski, W. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i29.3603 · Cited by 174
Raoul, J., Bruix, J., Greten, T. F., Sherman, M., Mazzaferro, V., Hilgard, P. A., Scherübl, H., Scheulen, M. E., Germanidis, G. S., Dominguez, S., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.009 · Cited by 131
Hsu, C., Yang, T.-S., Hsu, C., Toh, H. C., Epstein, R. J., Hsiao, L.-T., Chen, P.-J., Lin, Z.-Z., Chao, T.-Y., & Cheng, A.-L. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605580 · Cited by 131
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
Hollebecque, A., Cattan, S., Romano, O., Sergent, G., Mourad, A., Louvet, A., Dharancy, S., Boleslawski, E., Truant, S., Pruvot, F., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04860.x · Cited by 119
Lencioni, R. A., Kudo, M., Ye, S.-L., Bronowicki, J., Chen, X.-P., Dagher, L., Furuse, J., Geschwind, J. F., de Guevara, L. L., Papandreou, C. N., et al. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02940.x · Cited by 111
Abou‐Alfa, G. K., Amadori, D., Santoro, A., Figer, A., Grève, J. D., Lathia, C. D., Voliotis, D., Anderson, S. E., Moscovici, M., & Ricci, S. (2011) · Europe PMC (PubMed Central) · Cited by 109
Kang, Y., Yau, T. C. C., Park, J.-W., Lim, H. Y., Lee, T.-H., Obi, S., Chan, S. L., Qin, S., Kim, R. D., Casey, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv388 · Cited by 103
Self-citationZhu, A. X., Kang, Y., Yen, C., Finn, R. S., Galle, P. R., Llovet, J. M., Assénat, E., Brandi, G., Lim, H. Y., Pracht, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4003 · Cited by 100
Sun, W., Sohal, D. P. S., Haller, D. G., Mykulowycz, K., Rosen, M. A., Soulen, M. C., Caparro, M., Teitelbaum, U. R., Giantonio, B. J., O'Dwyer, P. J., et al. (2011) · Cancer · doi:10.1002/cncr.25889 · Cited by 99
Self-citationQin, S., Cheng, Y., Liang, J., Shen, L., Bai, Y., Li, J., Fan, J., Liang, L., Zhang, Y., Wu, G., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0190 · Cited by 99
Crocenzi, T. S., El-Khoueiry, A. B., Yau, T. C., Melero, I., Sangro, B., Kudo, M., Hsu, C., Trojan, J., Kim, T., Choo, S.-P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4013 · Cited by 87
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
Kim, J. E., Ryoo, B., Ryu, M., Chang, H.-M., Suh, D. J., Lee, H. C., Lim, Y., Kim, K. M., & Kang, Y. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1616-x · Cited by 85
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
Pinter, M., Sieghart, W., Hucke, F., Graziadei, I., Vogel, W., Maieron, A., Königsberg, R., Weißmann, A.-C., Kornek, G. V., Matejka, J., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04823.x · Cited by 77
Chiu, J. W. Y., Tang, Y. F., Yao, T., Wong, A., Wong, H., Leung, R. C.-Y., Chan, P., Cheung, T. T., Chan, A. C. Y., Pang, R. W. C., et al. (2012) · Cancer · doi:10.1002/cncr.27543 · Cited by 69
Takamatsu, S., Noguchi, N., Kudo, A., Nakamura, N., Kawamura, T., Teramoto, K., Igari, T., & Arii, S. (2008) · PubMed · Cited by 62
Selection of Patients with Hepatocellular Carcinoma for Sorafenib
Abou‐Alfa, G. K. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0028 · Cited by 37
Cited by
Garin, E., Tselikas, L., Guiu, B., Chalaye, J., Edeline, J., de Baere, T., Assenat, E., Tacher, V., Robert, C., Terroir-Cassou-Mounat, M., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30290-9 · Cited by 630
Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms
Parikh, N. D., Singal, A. G., Hutton, D. W., & Tapper, E. B. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000715 · Cited by 163
Metadata
- Authors
- Benson, A. B., D’Angelica, M. I., Abbott, D. E., Abrams, T. A., Alberts, S. R., Anaya, D. A., Anders, R., Are, C., Brown, D., Chang, D. T., Cloyd, J., Covey, A. M., Hawkins, W., Iyer, R., Jacob, R., Karachristos, A., Kelley, R. K., Kim, R., Palta, M., Park, J. O., Sahai, V., Schefter, T., Sicklick, J. K., Singh, G., Sohal, D., Stein, S., Tian, G. G., Vauthey, J.-N., Venook, A. P., Hammond, L. J., & Darlow, S. D.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2019-04
- Volume
- 17
- Issue
- 4
- Pages
- 302-310
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2972268711
- Cited by
- 269
- References
- 41
- FWCI
- 25.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.